Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Inovio Pharmaceuticals Inc (INO) vs Mizuho Financial Group Inc. Sponosred ADR (Japan) (MFG) Price & Performance

Inovio Pharmaceuticals IncTrade
Mizuho Financial Group Inc. Sponosred ADR (Japan)Trade

Price performance (Past 24H)

Key statistics

Inovio Pharmaceuticals Inc vs Mizuho Financial Group Inc. Sponosred ADR (Japan) — how do they compare? Inovio Pharmaceuticals Inc trades at $1.1 (market cap $112.19M), while Mizuho Financial Group Inc. Sponosred ADR (Japan) trades at $10.46 (market cap $127.85B). The key difference: Mizuho Financial Group Inc. Sponosred ADR (Japan) is far larger — about 1139.6× Inovio Pharmaceuticals Inc's market cap, and Mizuho Financial Group Inc. Sponosred ADR (Japan) pays a 1.72% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Mizuho Financial Group Inc. Sponosred ADR (Japan) for 0 Days on average.

INOMFG
Market Cap
$112.19M$127.85B
Volume
3,201,2783,950,750
Sector
HealthFinancials
52-Week High
$2.65$11.45
52-Week Low
$0.66$6.09
Typical Hold Time
43 Days0 Days
Enterprise Value
$83.51M$35.14T
Dividend Yield
—1.72%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals (INO) trades at $1.155, up 2.21% today, while showing bearish technical signals with negative cash flow and substantial losses. The company's financials reveal minimal revenue of $65,340 against an $84.95 million net loss in 2025, with profitability metrics deeply negative. However, analyst sentiment is optimistic with a 58.83% buy rating and $2.75 consensus price target, driven by the upcoming FDA decision on INO-3107 for recurrent respiratory papillomatosis by October 30, 2026.

INO presents high-risk speculation with potential for significant upside if FDA approval is secured, but carries substantial fundamental weaknesses including persistent cash burn and negative margins. Investors should weigh the binary outcome of the regulatory decision against the company's challenging financial position and technical bearishness.

Mizuho Financial Group Inc. Sponosred ADR (Japan)

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

INO
95% Buy5% Sell
Avg holding period · 43 Days
MFG
100% Buy0% Sell
Avg holding period · 0 Days

About Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Read more on INO →

About Mizuho Financial Group Inc. Sponosred ADR (Japan)

Mizuho Financial Group is a Japanese financial services company offering banking, trust, securities, and asset management services. It serves retail, corporate, and institutional clients globally.

Read more on MFG →